Emerging Horizons on Molecular and Circulating Biomarkers in Pancreatic Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 22

PMID 39575418

Authors

Marta Moretti

Antonella Farina

Antonio Angeloni

Emanuela Anastasi

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive and invasive type of pancreatic cancer and is expected to soon become the second leading cause of cancer-associated death. The high mortality rate is due to the clinical features that allow asymptomatic progression to advanced stages, a period when current therapeutic treatments have limited efficacy. To address these challenges, researchers are focused on identifying new molecular and circulating markers for early PDAC detection and precision medicine. In this mini-review, we report the most well-known and recently identified molecular and circulating biomarkers. This study aimed to emphasize the need for continued innovative research to develop diagnostic algorithms and therapies to improve the management of patients with PDAC.

References

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

ONeill R, Stoita A . Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?. World J Gastroenterol. 2021; 27(26):4045-4087. PMC: 8311531. DOI: 10.3748/wjg.v27.i26.4045. View

Huang L, Goodrow T, Zhang S, Klein-Szanto A, Chang H, Ruggeri B . Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 1996; 56(5):1137-41. View

Li P, Cao G, Zhang Y, Shi J, Cai K, Zhen L . FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging (Albany NY). 2020; 12(1):53-69. PMC: 6977653. DOI: 10.18632/aging.102564. View

Lowery M, Kelsen D, Stadler Z, Yu K, Janjigian Y, Ludwig E . An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011; 16(10):1397-402. PMC: 3228075. DOI: 10.1634/theoncologist.2011-0185. View

Wang W, Liu L, Xu H, Wu C, Xiang J, Xu J . Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg. 2016; 103(9):1189-99. DOI: 10.1002/bjs.10187. View

Aldyab M, Jabbour T, Parilla M, Lee H . Benign malignant pancreatic lesions: Molecular insights to an ongoing debate. World J Gastrointest Surg. 2021; 13(5):406-418. PMC: 8167846. DOI: 10.4240/wjgs.v13.i5.406. View

Taniguchi T, Kishi K, Nakagawa T, Tanaka H, Tanaka T, Tomonari T . Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma. Digestion. 2017; 95(3):242-251. DOI: 10.1159/000470837. View

Zienert E, Eke I, Aust D, Cordes N . LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells. Cancer Lett. 2015; 364(1):17-24. DOI: 10.1016/j.canlet.2015.04.019. View

10.

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

11.

Hao Z, Jin D, Chen X, Schurgers L, Stafford D, Tie J . γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K-dependent proteins. Blood. 2021; 137(4):533-543. PMC: 7845004. DOI: 10.1182/blood.2020006329. View

12.

Schoeps B, Eckfeld C, Prokopchuk O, Bottcher J, Haussler D, Steiger K . TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Cancer Res. 2021; 81(13):3568-3579. DOI: 10.1158/0008-5472.CAN-20-4125. View

13.

Jahangiri L . A mechanistic insight into cancer progression mediated by Nucleoporins. Cancer Genet. 2024; 286-287:35-42. DOI: 10.1016/j.cancergen.2024.07.001. View

14.

Niland S, Riscanevo A, Eble J . Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2022; 23(1). PMC: 8745566. DOI: 10.3390/ijms23010146. View

15.

Yang J, Xu R, Wang C, Qiu J, Ren B, You L . Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun (Lond). 2021; 41(12):1257-1274. PMC: 8696234. DOI: 10.1002/cac2.12204. View

16.

Bugazia D, Al-Najjar E, Esmail A, Abdelrahim S, Abboud K, Abdelrahim A . Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments. Front Oncol. 2024; 14:1386699. PMC: 11247645. DOI: 10.3389/fonc.2024.1386699. View

17.

Barthel S, Falcomata C, Rad R, Theis F, Saur D . Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Nat Cancer. 2023; 4(4):454-467. PMC: 7615362. DOI: 10.1038/s43018-023-00526-x. View

18.

Ozkan H, Demirbas S, Ibis M, Akbal E, Koklu S . Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases. Pancreatology. 2011; 11(3):295-300. DOI: 10.1159/000328963. View

19.

Brozos-Vazquez E, Toledano-Fonseca M, Costa-Fraga N, Garcia-Ortiz M, Diaz-Lagares A, Rodriguez-Ariza A . Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treat Rev. 2024; 125:102719. DOI: 10.1016/j.ctrv.2024.102719. View

20.

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C . Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019; 14(1):141. PMC: 6688256. DOI: 10.1186/s13014-019-1345-6. View